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SUMMARY
The incidence of hepatitis delta virus (HDV) infection in Northern Ireland
(1970-1989) was tested by enzyme linked immunosorbent assay in 401
hepatitis B surface antigen (HBsAg)positive sera. Hepatitis delta antigen (HDAg)
was tested in 388 patients and antibody to delta antigen (anti-HD) in 401
patients. Four patients (1 -03 %) were HDAg positive. Nine patients (2-24 %)
werepositiveforanti-HD andafter acidpre-treatment ofsera from eight ofthese
patients, five were positive for HDAg. The overall incidence ofHDVmarkers was
3-27%, which reflects the low incidence in HBsAg carriers in Northern Ireland
(who were in high riskgroups fordelta hepatitis). The use ofacid treatment ofthe
sera to break up antigen/antibody complexes has been a useful technological
improvement in the identification of this virus.
INTRODUCTION
The hepatitis delta virus is unique among virus-like agents. It is a defective virus
that requires active helper functions from the hepatitis B virus (HBV) for its
replication. The hepatitis delta virus is approximately 36nm in diameter with an
RNA core and an HBsAg coat. Infection with HDV, therefore, may occur in
patients with acute or chronic HBV infections and in the latter is often associated
with severe and progressive liver disease, including chronic active hepatitis and
cirrhosis. HDV has also been implicated in cases of fulminant hepatitis, occasion -
ally in epidemic form. The incidence of delta virus infection in certain hepatitis B
virus populations may be used as a surrogate indicator of intravenous drug use.
PATIENTS, MATERIALS AND METHODS
Four hundred and one HBsAg positive sera were stored at - 200C from
1970 - 89. Three hundred and eighty eight were tested for the presence of
HDAg and 401 for anti-HD by enzyme linked immunosorbent assay (ELISA).
These included sera from cases of hepatitis from all parts of Northern Ireland
and carriers discovered by screening of blood donors and ante-natal patients by
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the Northern Ireland Blood Transfusion Service. Nineteen sera from haemo-
philiacs with hepatitis B antibodies (anti-HBs) were also studied and tested for
anti-HD.
The Organon Teknika Hepanostika anti-Delta Microelisa test was used. The
HDAg test was based on a direct "sandwich" using 6% Tween 20 and overnight
incubation at room temperature. The anti-HD test was based on a competitive
"sandwich" inhibition method. Sera from eight patients with anti-HD were pre-
treated with 0-5N HCI as previously described' for detection of HDAg. Sera
which tested positive for HDAg or anti -HD were repeat tested.
RESULTS
Three hundred and eighty-eight HBsAg positive sera were tested for HDAg and
401 HBsAg positive sera and 19 anti-HBs positive sera were tested for anti-HD.
The groups of patients with positive HDV markers are shown in Table 1.
TABLE I
Groups ofHBsAg positive patients showing evidence ofHDV infection
Group Tested Positive % Positive
HDAg Anti-HD HDAg Anti-HD HDAg Anti-HD
Haemophiliacs 9 28* 0 (1)* * 2 0 (1 I 1 %)** 7-1%
Intravenous drug abusers 20 20 1 0 5 0% 0
Post surgery 21 21 0 (1)** 1 0 (4 8%)** 4-8%
Foreign -born adults or
foreign contacts 141 153 3 (3)** 4 2-1 (2-1)** 2-6%
Blood donors 47 47 0 2 0 4-3%
*Includes sera from 19 haemophiliacs with anti-HBs.
* *Figures in brackets show additional HDAg positive sera after acid pre-treatment.
The results show that thehighest incidenceof HDV infection was in haemophiliacs
followed by intravenous drug abusers, post surgery, foreign -born adults and
foreign contacts, and blood donors. Other groups of patients including health
care workers, recipients of multiple transfusions, sexual or perinatal contacts, the
recently tattooed, antenatal patients or organ donors did not show evidence of
HDV infection.
Further details of the patients positive for HDV markers are shown in Table 11.
DISCUSSION
The epidemiology of HDV infection is closely linked to the epidemiology of HBV
infection. There is a lower incidence of HBV infection in Northern Ireland than in
the rest of the United Kingdom,2 and one would expect the incidence of HDV
infection to be lower. In addition there has been a marked fall in HBV infections in
the United Kingdom since 1984,3 probably due to publicity about AIDS which
will further decrease the risk of HDV infection.
The highest incidence of HDV infection was seen in haemophiliacs, which
correlates with their need for transfusions or blood products. HBsAg infection in
these patients has not occurred since 1982, probably due to more sensitive
HBsAg screening of blood.2
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TABLE II
Patients with evidence ofHDV infection
Clinical status
HDAg Positive
1976
1982
1986
1986
25
8
35
64
Anti-HD Positive
1974* 21
1987 53
1982* 59
1981* 27
1988* 40
1983* 27
1988 26
1986 42
1979 -
M
M
M
F
M
M
M
M
M
M
M
F
M
Intravenous drug abuser (London)
Vietnamese
Laboratory worker (Guyana)
Hepatitis acquired 8 years
previously in Greece
Haemophiliac
Haemophiliac
Surgery in previous 2 years
Ethiopian
Iranian (previous hepatitis in Africa)
Chinese
Gilbert Islands citizen
Blood donor
Blood donor
Acute hepatitis (1976)
HBsAg carrier
Acute hepatitis (1985)
Chronic active hepatitis
Acute hepatitis (1972)
Acute hepatitis (1973)
Cirrhosis
Acute hepatitis
Chronic active hepatitis
HBsAg carrier
HBsAg carrier
HBsAg carrier
HBsAg carrier
*HDAg positive after acid pre-treatment of sera.
There is a small but not negligible risk of HBV infection from HBsAg negative,
HB core antigen (HBcAg) positive blood not detected by screening for HBsAg in
donated blood. The riskoftransmission of HDV infection in this wayis even lower,
and additional testing of HBsAg negative blood for HDV is unlikely to reduce this
risk since HDV serum markers detected usually reflect past rather than current
infection. The HBsAg positive recipient, however, is at high risk for HDV infection
from HBcAg positive blood.4
Only 20 HBsAg positive drug abusers were available for study and one (5*0%)
had HDV antigen. This patient acquired his HDV infection in London. Intravenous
drug abuse is a small problem in Northern Ireland.5 Hepatitis associated with
HDV infection was first found among intravenous drug abusers in Italy. Studies
in the United Kingdom and Republic of Ireland (West of Scotland,6 South East
London,7 Merseyside8 and Dublin9) have shown that HDV infection is largely
confined to intravenous drug abusers and their social and sexual contacts.
The post-surgical patient with HDV markers in this study presented with cirrhosis
of unknown origin. The only known risk factor was a total hip replacement two
years previously. There were no apparent sources of HDV infection for the two
blood donors found to be positive.
About one third ofHBsAg positive patients in Northern Ireland were foreign -born
or had foreign contacts, and most ofthese were ofChinese or Vietnameseorigin.2
Half of the patients with HDV markers in Northern Ireland (7/13) were foreign-
born or had contact with HBV in a foreign country. In our study only two patients
from the far east had evidence of HDV infection. It is not known why HDV
infection is uncommon in HBsAg carriers in South East Asia and China wherethe
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prevalenceof HBV infection is very high. Delta virus infection is endemicin certain
populations and is especially common in the Mediterranean area and the middle
east, the highest prevalence being reported from Kuwait and Saudi Arabia. The
health care worker in our study was a laboratory worker in Jamaica and also in
Georgetown, Guyana, which is proximal to known epidemic foci. There are
known epidemic foci in Colombia,I0 Venezuela II and the Amazon basin, but delta
hepatitisis rarein Northern Europe, the United Statesand mostofSouthAmerica.
One patient in the study was from the Gilbert Islands. The incidence of HDV
infection in the Western Pacific region is very low apart from high prevalence foci
in Polynesia and Micronesia. 12
Delta virus infection can only occur in the presence of existing HBV infection,
but HDV interferes with the replication of HBV.13 Clinically, delta virus hepatitis
resembles other forms of acute and chronic hepatitis but it tends to be more
severe. Acute delta hepatitis occurs in two forms. In co
-infection HBV and HDV
are acquired together and the clinical picture is indistinguishable from acute HBV
hepatitis, but there is a higher incidence of fulminant hepatitis with a higher
mortality. In superinfection, acute HDV infection occurs in a chronic HBV carrier
which often leads to chronic hepatitis. Chronic delta hepatitis usually progresses
from superinfection and may have a rapid course to cirrhosis. The diagnosis of
acute HDV infection rests on detection of HDAg in blood in the first three or four
weeks of illness, or the presence of anti
- HD which appears on average more than
four weeks later. Acid pre-treatment of sera containing anti-HD in our study
showed that an anti-HD/HDAg complex was present. The HDAg was split off at
acid pH and could then be detected, but it would not be known ifit was infectious.
In chronic HDV infection, HDAg may be detected in serum by immunoblotting
although it may be complexed with antibody.'4 In HDV infected HBsAg carriers,
high titre IgM anti-HD is a useful indicator of chronic HDV infection and will
distinguish between patients with chronic HDV infection and those with previous
exposure.'5 Comparison of five HDV assays showed that the Organon Teknika
assay as used in this study was the most sensitive for HDAg detection.'6 The use
of acid treatment ofthe sera to break up antigen/antibody complexes has been a
useful technological improvement in the identification of this virus.
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